Axsome Advances AXS-12 Toward NDA for Narcolepsy
NEW YORK | December 31, 2025 — Axsome Therapeutics announced it has received formal FDA pre–New Drug Application (Pre-NDA)...
GCP compliance
Advertisement
Celularity Strengthens Platform With Strategic Financing Close
Florham Park, New Jersey | December 22, 2025 — Celularity Inc., a regenerative and cellular medicine company focused on...
IRLAB Wins Approval for Phase Ib IRL757 Parkinson’s Trial
Gothenburg, Sweden | December 23, 2025 — IRLAB Therapeutics AB announced that it has received regulatory and ethical approvals...
Faron Launches BLAZE Trial to Overcome Immunotherapy Resistance
TURKU, Finland; LONDON, United Kingdom — December 22, 2025 — Faron Pharmaceuticals Ltd, a clinical-stage biopharmaceutical company, has announced...
Mondego Bio Names PTPN2 Inhibitor for First-in-Human Study
CANTANHEDE, Portugal — December 22, 2025 — Mondego Bio has announced the formal selection of ZE00-0388, a highly selective...
Advertisement
